IDXG 8-K
Interpace Biosciences, Inc. (IDXG)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address, including zip code, of Principal Executive Offices)
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 9, 2023, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the quarter ended June 30, 2023. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 | Press Release, dated August 9, 2023 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Interpace Biosciences, Inc. | ||
| By: | /s/ Thomas W. Burnell | |
| Name: | Thomas W. Burnell | |
| Title: | President and Chief Executive Officer | |
Date: August 9, 2023
Exhibit 99.1
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
| ● | Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history | |
| ● | Q2 Test volume up 15% year over year to record levels | |
| ● | Q2 Reimbursement improvement up 34% year-over-year driven by additional commercial contracts and collection initiatives |
PARSIPPANY, NJ, August 9, 2023 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financial update.
Second quarter Net Revenue was $11.0 million, a $3.6 million increase over second quarter 2022. Income from continuing operations in the second quarter of 2023 was $0.4 million, an improvement of $2.5 million from the prior year quarter’s loss of $2.1 million. On an adjusted basis, EDITDA was $1.3 million in Q2 and $2.6 million for H1 2023. Excluding one-time charges of $0.6 million in Q2 and $0.9 million in H1 for exploring changes to the existing capital structure, adjusted EBITDA on an operating basis was $2.0 million and $3.5 million for Q2 and H1, respectively.
“As reported in our preliminary Q2 business results published July 10, 2023, the Company achieved record volume, revenue, income and cash collections in Q2”, said Chris McCarthy, Chief Financial Officer. Tom Burnell, President and CEO added, “the strength and stability of our Company driven by growing adoption and utilization of our well-recognized thyroid and pancreatic cancer molecular diagnostics tests, and supported by a strong team of professional employees, has yielded results far-exceeding initial expectations”. “We are pleased with the trajectory of the Company despite the industry-wide challenges associated with Molecular diagnostic reimbursement from the Centers for Medicare and Medicaid Services”, said Dr. Burnell. Finally, Burnell added, “with regard to these challenges, we intend to present strong arguments to Novitas supporting the long-standing and well demonstrated clinical utility of our Pancragen test, and why we believe this test should be removed from the Proposed LCD issued by Novitas on July 27, 2023. We expect a final resolution by Novitas and CMS will require several months to a year, and in the meantime, we will remain steadfast and diligently focused on market penetration, operational efficiency, and cost-effectiveness all while maintaining a compassion for patient care and enhancing shareholder value.”
Second Quarter and 2023 Financial Performance
For the Second Quarter of 2023 as Compared to the Second Quarter of 2022
| ● | Net Revenue was $11.0 million, an increase of 49% from $7.4 million for the prior year quarter | |
| ● | Gross Profit percentage was 62% compared to 52% for the prior year quarter, a 19% improvement over prior year | |
| ● | Operating income was $0.8 million vs an operating loss of $(1.9) million in the prior year quarter | |
| ● | Income from continuing operations was $0.4 million vs a loss from continuing operations of $(2.1) million in the prior year quarter | |
| ● | Adjusted EBITDA was $1.3 million vs $(1.6) million loss in the prior year quarter | |
| ● | Q2 2023 cash collections totaled $10.2 million vs $8.3 million for Q2 2022 | |
| ● | June 30, 2023 cash balance increased $3.2 million to $5.1 million. June 30, 2022 cash balance was $1.9 million, net of restricted cash |
For the Six Months Ended June 30, 2023 as Compared to the Six Months Ended June 30, 2022
| ● | Net Revenue was $20.9 million, an increase of 36% from $15.3 million for the prior year | |
| ● | Gross Profit percentage was 61% compared to 55% for the prior year quarter, an 11% improvement year over year | |
| ● | Income from continuing operations was $0.8 million vs a loss from continuing operations of $(3.2) million in the prior year | |
| ● | Adjusted EBITDA was $2.6 million vs $(1.9) million loss in the prior year |
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has five commercialized molecular tests and one test in a clinical evaluation program (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA®, a “molecular only” version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay; ThyraMIR®v2, used in combination with ThyGeNEXT®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification; and RespriDX®, that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN®, a molecular-based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a CEP, whereby we gather information from physicians using BarreGEN to assist us in gathering clinical evidence relative to the safety and performance of the test and also providing data that will potentially support payer reimbursement.
For more information, please visit Interpace Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the reimbursement of the Company’s tests being subject to review by CMS, the Company’s ability to continue to perform, bill and receive reimbursement for our PancraGEN® molecular test under the existing local coverage determination (“LCD”), given that such LCD is currently under review by Novitas Solutions, Inc., the Company’s Medicare administrative contractor, the possibility that the Company’s estimates of future revenue, cash flows and adjusted EBITDA may prove to be materially inaccurate, the Company’s history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings with Comerica Bank and BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect, and the possible removal of the Company’s common stock from trading on the OTCQX®.
Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts:
Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
INTERPACE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share data)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue, net | $ | 11,026 | $ | 7,395 | $ | 20,853 | $ | 15,318 | ||||||||
| Cost of revenue | 4,191 | 3,565 | 8,039 | 6,830 | ||||||||||||
| Gross Profit | 6,835 | 3,830 | 12,814 | 8,488 | ||||||||||||
| Sales and marketing | 2,605 | 2,551 | 4,947 | 4,751 | ||||||||||||
| Research and development | 186 | 204 | 335 | 435 | ||||||||||||
| General and administrative | 2,894 | 2,983 | 5,389 | 5,869 | ||||||||||||
| Acquisition amortization expense | 318 | 317 | 635 | 635 | ||||||||||||
| Change in fair value of contingent consideration | - | (311 | ) | - | (311 | ) | ||||||||||
| Total operating expenses | 6,003 | 5,744 | 11,306 | 11,379 | ||||||||||||
| Operating income (loss) | 832 | (1,914 | ) | 1,508 | (2,891 | ) | ||||||||||
| Interest accretion expense | (31 | ) | 36 | (66 | ) | (85 | ) | |||||||||
| Note payable interest | (228 | ) | (210 | ) | (453 | ) | (390 | ) | ||||||||
| Other (expense) income, net | (174 | ) | 37 | (156 | ) | 198 | ||||||||||
| Income (loss) from continuing operations before tax | 399 | (2,051 | ) | 833 | (3,168 | ) | ||||||||||
| Provision for income taxes | 4 | 16 | 8 | 34 | ||||||||||||
| Income (loss) from continuing operations | 395 | (2,067 | ) | 825 | (3,202 | ) | ||||||||||
| Loss from discontinued operations, net of tax | (220 | ) | (1,872 | ) | (299 | ) | (2,984 | ) | ||||||||
| Net income (loss) | $ | 175 | $ | (3,939 | ) | $ | 526 | $ | (6,186 | ) | ||||||
| Basic income (loss) per share of common stock: | ||||||||||||||||
| From continuing operations | $ | 0.09 | $ | (0.49 | ) | $ | 0.19 | $ | (0.76 | ) | ||||||
| From discontinued operations | (0.05 | ) | (0.44 | ) | (0.07 | ) | (0.71 | ) | ||||||||
| Net loss per basic share of common stock | $ | 0.04 | $ | (0.93 | ) | $ | 0.12 | $ | (1.47 | ) | ||||||
| Diluted income (loss) per share of common stock: | ||||||||||||||||
| From continuing operations | $ | 0.09 | $ | (0.49 | ) | $ | 0.19 | $ | (0.76 | ) | ||||||
| From discontinued operations | (0.05 | ) | (0.44 | ) | (0.07 | ) | (0.71 | ) | ||||||||
| Net loss per basic share of common stock | $ | 0.04 | $ | (0.93 | ) | $ | 0.12 | $ | (1.47 | ) | ||||||
| Weighted average number of common shares and | ||||||||||||||||
| common share equivalents outstanding: | ||||||||||||||||
| Basic | 4,311 | 4,229 | 4,309 | 4,219 | ||||||||||||
| Diluted | 4,316 | 4,229 | 4,313 | 4,219 | ||||||||||||
Selected Balance Sheet Data (Unaudited)
($ in thousands)
| June 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Cash and cash equivalents | $ | 5,079 | $ | 4,828 | ||||
| Total current assets | 12,975 | 12,154 | ||||||
| Total current liabilities | 13,565 | 14,283 | ||||||
| Total assets | 15,942 | 15,979 | ||||||
| Total liabilities | 31,612 | 32,515 | ||||||
| Total stockholders’ deficit | (62,206 | ) | (63,072 | ) | ||||
Selected Cash Flow Data (Unaudited)
($ in thousands)
| For the Six Months Ended | ||||||||
| June 30, | ||||||||
| 2023 | 2022 | |||||||
| Net income (loss) | $ | 526 | $ | (6,186 | ) | |||
| Net cash provided (used in) operating activities | $ | 1,544 | $ | (4,172 | ) | |||
| Net cash used in investing activities | (293 | ) | (86 | ) | ||||
| Net cash (used in) provided by financing activities | (1,000 | ) | 3,059 | |||||
| Change in cash, cash equivalents and restricted cash | 251 | (1,199 | ) | |||||
| Cash, cash equivalents and restricted cash – beginning | 4,828 | 3,314 | ||||||
| Cash, cash equivalents and restricted cash – ending | $ | 5,079 | $ | 2,115 | ||||
Reconciliation of Adjusted EBITDA (Unaudited)
($ in thousands)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Income (loss) from continuing operations (GAAP Basis) | $ | 395 | $ | (2,067 | ) | $ | 825 | $ | (3,202 | ) | ||||||
| Depreciation and amortization | 357 | 351 | 714 | 723 | ||||||||||||
| Stock-based compensation | 157 | 305 | 349 | 608 | ||||||||||||
| Taxes expense | 4 | 16 | 8 | 34 | ||||||||||||
| Interest accretion expense | 31 | (36 | ) | 66 | 85 | |||||||||||
| Note payable interest | 228 | 210 | 453 | 390 | ||||||||||||
| Mark to market on warrant liability | - | (5 | ) | - | (68 | ) | ||||||||||
| Change in fair value of note payable | 165 | (53 | ) | 142 | (160 | ) | ||||||||||
| Change in fair value of contingent consideration | - | (311 | ) | - | (311 | ) | ||||||||||
| Adjusted EBITDA | $ | 1,337 | $ | (1,590 | ) | $ | 2,557 | $ | (1,901 | ) | ||||||
Non-GAAP Financial Measures
In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.
In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock based compensation and ESPP plans, interest and taxes, and other non-cash expenses including change in fair values of notes payable, contingent consideration and warrant liability. The table above includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.